Hikma Pharmaceuticals PLC posted robust financial results for 2024, with revenue climbing 9% to $3.127 billion compared to $2.875 billion in 2023, according to audited figures released Wednesday. The ...

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...

BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...

The current approval of Takeda’s Takhzyro pre-filled pen is an addition to the existing 150 mg and 300 mg pre-filled syringes ...

BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...

Takeda, a global biopharmaceutical company with a manufacturing site in Stanton Springs, unveiled its new Biomedical Waste ...

President Donald Trump has warned a group of major U.S. drugmakers that his administration is set to impose tariffs on pharmaceutical goods, and they should start moving their manufacturing businesses ...

We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...

Recursion Pharmaceuticals, Inc.’s RXRX share price has dipped by 10.34%, which has investors questioning if this is right time to buy.

CEOs emphasize the need to stay nimble and rethink supply chains as barriers to trade are erected in an increasingly ...